Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-708163 125 mg in Healthy Japanese and Non-Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 19 Jul 2012
At a glance
- Drugs Avagacestat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 19 Jul 2012 Pharmacokinetic results presented at the 2012 International Conference on Alzheimer's Disease.
- 19 Jul 2012 Results presented at the 2012 International Conference on Alzheimer's Disease.
- 26 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.